The AffloVest is battery-operated and uses Direct Dynamic Oscillation technology, which closely mimics hand CPT (Chest Physical Therapy) to help mobilise and clear secretions from the lungs, and allows for full freedom of mobility during treatment.
Doctors prescribe AffloVest for patients across a range of ages who have severe respiratory diseases such as bronchiectasis, cystic fibrosis, and certain neuromuscular diseases.
This next generation AffloVest, which began shipping September 1, is much lighter, quieter, and more efficient, with a smaller profile battery and long-life, state-of-the-art motors, offering improved patient ease of use.
The new AffloVest is on average 2 pounds lighter (more than 20% less weight) than the previous version, and uses streamlined components and tailored styling for a sleeker, slimmer fit.
International Biophysics brings to market medical devices and technologies aimed at improving treatment therapies and patient outcomes.
The company's precision ISO 13485 certified, FDA registered, quality controlled US manufacturing facility is located in Austin, Texas.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera